AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Recent findings suggest that recurrent pericarditis (RP) may be a previously unrecognized
autoinflammatory disease. The pivotal pathogenic role of interleukin (IL)-1 in RP has been
shown by the achievement of complete responses after treatment with the recombinant
IL-1-receptor antagonist, anakinra. Anakinra is the recombinant form of IL-1Ra. The proposed
study is designed to demonstarate the efficacy of anakinra in RP.